Microdosing a GLP-1: what it means and what has been tested
Reviewed 18 sourcesPublished by PepVault
What microdosing semaglutide or tirzepatide means, why no trial has results yet, and what the lowest label doses did in SURMOUNT-MAINTAIN, SUSTAIN and others.

- Last reviewed
- Sources
- 18
- Questions
- 6
- Compounds
- 3
The short answer
Microdosing a GLP-1 means taking less than the label's lowest step, or spacing shots further apart; it has no medical definition. No trial has reported results: one randomized study is registered, with nothing published as of November 2026. The closest data are label doses: in SURMOUNT-MAINTAIN, people who dropped to tirzepatide 5 mg kept 16.6% weight loss, against 21.9% on 10 or 15 mg. Dose changes are a prescriber's call.
Evidence: No trial results for microdosing as of November 2026: one registered randomized study without results and one observational cohort. The dose data are from randomized label and dose-finding trials, and the spacing data from one retrospective case series.

What do people mean by microdosing a GLP-1?
Three different things, and none of them is a medical term. A 2026 review in Minerva Endocrinology defines a microdose as any dose lower than the lowest approved dose, the starting dose on the label1. A 2026 commentary in Expert Opinion on Pharmacotherapy describes it as 25 to 50% of the starting dose, or longer gaps between doses2. Both papers name counting the clicks of a multi-dose pen's dial as a way people measure the small doses; Ozempic's own instructions say its starter pen delivers doses in 0.25 mg or 0.5 mg increments only124. Some also use it for staying on the lowest label step for months instead of moving up, a pattern one 2026 records study treats as a possible overlap9. Doses below the starting step and stretched gaps are off-label, meaning outside what the prescribing information describes, and the Minerva review notes that no manufacturer, regulator, scientific society or clinical guideline supports them1. Staying on the starting step falls outside Zepbound's label, which says 2.5 mg is not approved as a maintenance dosage5.
To know what sits below the lowest step, start with the steps themselves. Each label begins low and steps up after at least four weeks on a dose, and each says the climb is there to reduce the risk of gastrointestinal side effects3456.
| Brand | Starting dose | What the label calls it | Lowest maintenance dose |
|---|---|---|---|
| Wegovy (semaglutide, weekly shot) | 0.25 mg, weeks 1 to 4 | Starting dosage, followed by escalation to 0.5, 1 and 1.7 mg3 | 1.7 mg; 2.4 mg recommended for weight reduction3 |
| Ozempic (semaglutide, weekly shot) | 0.25 mg, weeks 1 to 4 | Initiation dosage; the pen table lists 0.25 mg for initiation and 0.5 mg for maintenance4 | 0.5 mg4 |
| Zepbound (tirzepatide, weekly shot) | 2.5 mg, weeks 1 to 4 | For treatment initiation and not approved as a maintenance dosage5 | 5 mg5 |
| Mounjaro (tirzepatide, weekly shot) | 2.5 mg | Starting dosage, raised in 2.5 mg steps if more blood-sugar control is needed6 | No separate maintenance dose named; maximum 15 mg6 |
Retatrutide, the fourth name people pair with microdosing in search, has no label to read a lowest step from: Drugs@FDA lists no approval for it as of November 202618.

Has any trial tested microdosing a GLP-1?
No trial has reported results. We searched ClinicalTrials.gov and PubMed on November 20, 2026, and found two registered studies that use the word, neither with results.
- AgelessRx, NCT07092605. The only randomized one: an early phase 1 study at one site, planning 150 healthy adults aged 18 to 65 who want microdoses for health and longevity and do not seek weight loss. They get compounded semaglutide under the tongue, compounded semaglutide by injection, or a placebo, weekly for up to 6 months. Its listed outcomes include self-reported pain, blood counts, basic blood chemistry, mood, heart-rate variability, sleep and activity from wearables. The record gives no dose amount. It started in November 2024 and was registered in July 2025; its estimated primary completion, November 2025, has passed with no results posted, and the record still reads enrolling by invitation, unchanged since July 20257.
- Noom, NCT07588984. An observational cohort, so people are not randomly assigned: it follows users of the company's programs, including arms on standard and "microdose" compounded semaglutide and tirzepatide, for up to 24 months. It began recruiting in May 2026 and estimates its primary completion for May 20298.
On microdosing itself, PubMed holds commentaries, letters and reviews, and one records study. It searched 29 million health records for people prescribed only the starting dose at least three times over six months or more: 814 on semaglutide 0.25 mg and 1,016 on tirzepatide 2.5 mg. Their average weight change at 12 months was −2.2% and −5.5%9. The authors say this prescribing pattern may overlap with microdosing but does not establish it, and records studies show associations, not causes9. The Expert Opinion commentary sums it up: high-quality evidence is essentially absent2.
How much weight did the lowest doses lose in trials?
The nearest real numbers come from trials that compared set doses with placebo, three of them with several doses side by side. Weight loss rose with the dose in all but one step, and even the smallest dose beat placebo.
| Trial | Who | Dose | Weeks | Weight change |
|---|---|---|---|---|
| O'Neil 2018, dose-finding10 | Obesity, no diabetes | Semaglutide 0.05 / 0.1 / 0.2 / 0.3 / 0.4 mg, injected daily | 52 | −6.0% / −8.6% / −11.6% / −11.2% / −13.8%; placebo −2.3% |
| SUSTAIN 111 | Type 2 diabetes | Semaglutide 0.5 / 1.0 mg weekly (Ozempic's steps) | 30 | −3.7 kg / −4.5 kg; placebo −1.0 kg |
| STEP 112 | Overweight or obesity | Semaglutide 2.4 mg weekly (Wegovy) | 68 | −14.9%; placebo −2.4% |
| SURMOUNT-113 | Obesity or overweight, no diabetes | Tirzepatide 5 / 10 / 15 mg weekly | 72 | −15.0% / −19.5% / −20.9%; placebo −3.1% |

Two cautions in reading it. The O'Neil arms were daily injections, a different schedule from today's weekly pens, so they do not map one to one onto the weekly steps; its 0.3 mg arm lost slightly less than 0.2 mg, and even its smallest arm, 0.05 mg a day, adds up to 0.35 mg a week, above the weekly pens' 0.25 mg start10. And the SUSTAIN 1 numbers are kilograms over 30 weeks in people with type 2 diabetes, so they do not line up with the percentage rows11. None of these arms was a dose below a label's starting step taken for months; that is exactly the untested part.
Can a lower dose keep the weight off after losing it?
One trial tested it, at a label dose. In SURMOUNT-MAINTAIN, 441 adults with obesity took tirzepatide for 60 weeks, at the highest dose each tolerated, 10 or 15 mg. Then 378 of them were randomly assigned, without knowing which, to stay on that dose, drop to 5 mg, or switch to placebo for another 52 weeks; from week 84, anyone who regained more than half the lost weight could get rescue tirzepatide14.
| Group after week 60 | Weight change from the start, week 112 | Received rescue tirzepatide after regaining more than half the loss |
|---|---|---|
| Stayed on 10 or 15 mg | −21.9% | 8% |
| Dropped to 5 mg | −16.6% | 25% |
| Switched to placebo | −9.9% | 67% |

The authors read the 5 mg result as a possible alternative to stopping, adding that individual response varies14. Note what it is not: 5 mg is a label maintenance dose, twice the starting step, so the trial says nothing about doses below the label514.
Spacing doses out has smaller evidence. A retrospective case series of 30 patients at one obesity practice, moved from weekly to mostly every-other-week shots at the same dose after their weight plateaued, reported average weight going from 74.1 kg to 72.4 kg over about 36 weeks17. With no comparison group, it shows what happened to those 30, not what spacing does. Two randomized trials of stepping down are registered and not yet recruiting: one tapers semaglutide 1.7 mg by 25% every 8 weeks against staying on it, and OFF-RAMP steps semaglutide down to 0.5 mg and tirzepatide to 5 mg every other week, against staying on the full dose or switching to a non-GLP-1 drug1516.
Why do people try smaller doses?
Mostly for the stomach, and for cost. The Expert Opinion commentary lists tolerability, cost and access during shortages as the reasons, with the practice spread through patient communities, telehealth programs and clinicians' anecdotes2. The side-effect logic has some trial support: in SUSTAIN 1, nausea was reported by 20% on 0.5 mg, 24% on 1.0 mg and 8% on placebo11, and the O'Neil trial called its gastrointestinal effects dose-related10. In SURMOUNT-1, adverse events led 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg to stop, against 2.6% on placebo13.
Commonly reported: people describe less nausea and a quieter appetite on small doses, with slower weight loss than on the full steps. The Expert Opinion commentary summarizes early reports the same way, as reduced nausea, better adherence and modest weight loss, from real-world reports rather than trials2.
Spacing shots out changes the level more than it sounds. Semaglutide's half-life, the time for the amount in the blood to fall by half, is about one week, and tirzepatide's about five days35. On a one-week half-life, about half a dose is left a week later and about a quarter two weeks later, so an every-other-week rhythm lets the level fall further between shots. The chart shows the build-up on the usual weekly rhythm.
Try it
How Semaglutide builds up
An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

What should you keep track of if your dose changes?
Whether a dose goes up, down or further apart is a treatment decision for your prescriber, and the trials above are what that conversation can start from. What helps either way is a clear record of what you took and what followed.
- Write down every dose as you actually took it, with the date, so a change is visible against the weeks before it.
- Weigh in on the same day of the week, at the same time, so the trend means something.
PepVault logs each dose as you record it and reminds you on your own schedule, weekly or every two weeks. Set reminders in PepVault
Its doctor's report puts your doses, weigh-ins and side effects for the protocol on one page to bring to your prescriber. Log it in PepVault
In STEP 1, nausea and diarrhea were mostly mild to moderate and eased with time12. The labels give one sign to act on at once: severe pain in the stomach area that will not go away, with or without nausea or vomiting, means stopping the drug and calling your healthcare provider right away35.
Sources
- Infante M et al. Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks. Minerva Endocrinol (Torino). 2026. PubMed 43021748
- Beck H, Clements JN. Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opin Pharmacother. 2026. PubMed 42788826
- Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed, revised June 2026. dailymed.nlm.nih.gov
- Ozempic (semaglutide) prescribing information, Novo Nordisk. DailyMed, June 2026. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) prescribing information, Eli Lilly. DailyMed, revised August 2026. dailymed.nlm.nih.gov
- Mounjaro (tirzepatide) prescribing information, Eli Lilly. DailyMed, revised August 2026. dailymed.nlm.nih.gov
- Effectiveness of microdosed GLP-1 in improving health, quality of life, and longevity measures (AgelessRx). ClinicalTrials.gov NCT07092605. clinicaltrials.gov
- GLP-1 medication and behavioral health on weight and metabolic outcomes: FLOURISH and THRIVE cohort study (Noom). ClinicalTrials.gov NCT07588984. clinicaltrials.gov
- Murugadoss K et al. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biol Methods Protoc. 2026. PubMed 42857675
- O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018. PubMed 30122305
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017. PubMed 28110911
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026. PubMed 42119587
- Evaluation of a semaglutide dose-tapering regimen for weight-loss maintenance in adults with overweight or obesity. ClinicalTrials.gov NCT07783854. clinicaltrials.gov
- OFF-RAMP feasibility: a pilot trial comparing off-ramping strategies for maintaining weight loss among adults using incretin-based therapies. ClinicalTrials.gov NCT07832084. clinicaltrials.gov
- Wong M et al. Reduced-frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series. Obesity (Silver Spring). 2026. PubMed 41732031
- Drugs@FDA: FDA-approved drugs (searched for retatrutide, November 20, 2026). accessdata.fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.